Name (Synonyms) | Correlation | |
---|---|---|
drug2281 | Sodium Nitrite Wiki | 0.71 |
drug2121 | SAB-185 Wiki | 0.50 |
drug215 | Ascorbic Acid Wiki | 0.35 |
drug1103 | Hydroxychloroquine Sulfate Wiki | 0.20 |
drug262 | Azithromycin Wiki | 0.12 |
drug1086 | Hydroxychloroquine Wiki | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
D055370 | Lung Injury NIH | 0.15 |
D013577 | Syndrome NIH | 0.08 |
D055371 | Acute Lung Injury NIH | 0.07 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.07 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.06 |
D007239 | Infection NIH | 0.04 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
There are 2 clinical trials
This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of intravenous Sodium Nitrite Injection for treatment of patients infected with COVID-19 who develop lung injury and require mechanical ventilation.
Description: Proportion of study subjects who are alive and free of respiratory failure at Day 28
Measure: Survival with Unassisted Breathing Time: Day 28Description: Number of days alive without mechanical ventilation from start of study through Day 28
Measure: Survival without Mechanical Ventilation Time: Day 28Description: Number of days alive and not in the intensive care unit from start of study through Day 28.
Measure: Survival without Intensive Care Time: Day 28Description: Number of days alive and not in hospital from start of study through Day 28.
Measure: Survival without Hospitalization Time: Day 28Description: Alive on Day 28 and no use of ECMO therapy any time between start of study and Day 28.
Measure: Survival without ECMO Time: Day 28Description: Alive on Day 28
Measure: Survival Time: Day 28Description: Oxygenation index (PaO2/FIO2) at Day 14
Measure: Lung Status Time: Day 14Description: Blood urea nitrogen (BUN) at Day 14
Measure: Kidney Status (1) Time: Day 14Description: Creatinine at Day 14
Measure: Kidney Status (2) Time: Day 14Description: Liver function tests (ALT and AST) at Day 14
Measure: Liver Status Time: Day 14: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19.
Description: Incidence and severity of other adverse events and severe adverse events (SAE)
Measure: Number of Participants Having Adverse Events Time: 29 DaysDescription: transfusion-related adverse events
Measure: Number of Participants Having Transfusion-Related Adverse Events Time: 29 DaysDescription: Incidence and severity of adverse events and SAEs from Screening through Study Day 90
Measure: Number of Participants Having Adverse Events Time: 90 DaysDescription: Measurement of SARS CoV-2 neutralizing (PRNT80) antibody titers from screening through Study Day 90
Measure: Assesment of the PD of SAB-185 administered intravenously Time: 90 DaysDescription: Measurement of Rheumatoid factor through day 90
Measure: Immune response elicited by SAB-185 Time: 90 DaysDescription: Measurement of anti-SAB-185 antibodies through screening day 90
Measure: Concentration of subject anti-SAB-185 antibodies elicited by SAB-185 Time: 90 DaysDescription: Incidence of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29
Measure: Incidence of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens Time: 29 DaysDescription: Level of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29
Measure: Level of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens Time: 29 Days